230P Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
Articles > Article · 2023
Authors: H.C. Yildirim, E. Mutlu, E. Chalabiyev, M. Ozen, M. Keskinkilic, Sercan ÖN, A. Celebi, B. Dursun, O. Acar, S. Kahraman, M.B. Aykan, O. Kaman, A. Dogan, A.P. Erdogan, O.M. Celayir, D.C. Guven, M. Polat Inanc, S. Kilickap, S. Yalcin, S. Aksoy
ESMO Open, International, WoS, 2023, vol 8, pp 101418-101418
DOI: 10.1016/j.esmoop.2023.101418
Summary
Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore, we aimed to investigate the treatment responses of metastatic HR+, HER2- male breast cancer patients treated with CDK 4-6 inhibitors in a multicenter real-life cohort.